CRISPR-Based Gene Editing Market Size, Share and Trends 2025 to 2034

CRISPR-Based Gene Editing Market Size and Forecast 2025 to 2034

The global CRISPR-based gene editing market size was estimated at USD 4.04 billion in 2024 and is predicted to increase from USD 4.46 billion in 2025 to approximately USD 13.39 billion by 2034, expanding at a CAGR of 13.00% from 2025 to 2034. The increased demand for target medical treatment solutions is driving the market. The advancements in gene editing technologies and growth in the biotechnology sector are boosting the CRISPR-based gene editing research and development.

CRISPR-Based Gene Editing Market Key Takeaways 

• North America dominated the market with the largest market share of 41.15% in 2024.
• Asia Pacific is expected to grow at a significant CAGR of 15.18% over the forecast period.
• By product, the kits and reagents segment held the biggest market share of 77% in 2024.
• By product, the services segment is projected to grow at a solid CAGR of 14.4% over the forecast period.
• By gene editing modality, the ex vivo editing segment contributed the biggest market share of 53% in 2024.
• By gene editing modality, the in vivo editing segment is growing at the fastest CAGR of 12.5% over the forecast period.
• By technology, the CRISPR/Cas9 technology segment held the major market share of 55% in 2024.
• By technology, the CRISPR/Cas12 technology segment is projected to grow at a notable CAGR of 12.3% during the forecast period.
• By application, the therapeutic applications segment contributed the highest market share of 64.05% in 2024.
• By application, the agriculture and livestock segment is expected to grow at a CAGR of 14.3% over the projected period.
• By end-user, the biotechnology and pharmaceutical companies segment accounted for the biggest market share of 42% in 2024.
• By end-user, the agricultural and livestock Industry segment is projected to grow at a CAGR of 14.3% during the forecast period.

How Artificial Intelligence (AI) is Advancing CRISPR-Based Gene Editing Therapies

The integration of Artificial Intelligence has a significant impact on the CRISPR-based gene editing market by enhancing gene editing precision, efficiency, and safety. The AI algorithm predicts the most effective guide RNA/DNA sequence for gene editing. AI models can reduce the risk of off-target events by predicting through analyzing genomic data. AI algorithms can help in developing novel gene editors by identifying the most suitable gene for editing.

Optimizing gene editing conditions, analyzing and predicting possible risks, and providing real-time monitoring help to enhance the efficiency and safety concerns of the CRISPR-based gene editing therapies. Automated data analytics and standardizing protocols help to reduce complexity and improve productivity, so AI is becoming a more acceptable and preferred tool in clinical trials. AI is gaining popularity in CRISPR-based gene editing to improve safety, optimize experiences to increase efficiency, and maintain clinical trial standardization.

U.S. CRISPR-Based Gene Editing Market Size and Growth 2025 to 2034

The U.S. CRISPR-based gene editing market size was exhibited at USD 940 million in 2024 and is projected to be worth around USD 2.95 billion by 2034, growing at a CAGR of 12.30% from 2025 to 2034.

North America: Early Adopter of CRISPR-based Gene Editing Technology

North America dominated the CRISPR-based gene editing market in 2024. North America is the early adopter of CRISPR gene editing technology. The presence of strong research and development institutes, as well as companies investing in the R&D ecosystem and innovation in CRISPR-based gene editing, is high in the region. Additionally, the presence of key market vendors and a favorable regulatory environment, with U.S. FDA approvals for novel development and approaches of CRISPR gene editing therapies, contributed to market growth. The existence of strong gene therapy businesses, such as those in biotechnology, the pharmaceutical industry, and research institutes, makes them the major adopters of CRISPR-based gene editing technology.

The United States is leading the regional market due to the presence of the major key players in the country. The United States has encouraged major agriculture industries to work on CRISPR-edited crop commercialization. Government initiatives and investments in biotechnology and the research and development sector allow advancements in the technology. With the increased incidence of genetic diseases and the support of government and regulations, the market is expected to continuously grow in the region.

• In January 2025, Allogene Therapeutics received the FDA IND clearance for its ALLO-329, an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, to target both CD19+ B-cells and CD70+ activated T-cells to eliminate dysfunctional cells of both types.

Regulatory Initiatives Boosting Technology Research and Development in Asia

Asia Pacific is expected to grow at a significant CAGR in the CRISPR-based gene editing market over the forecast period. Asia Pacific has witnessed a rapid expansion of the biotechnology industry, driven by highly skilled workforces, government support, and investments. The increasingly significant investment in research and development is fueling the CRISPR-based gene editing technology innovations. Growth in biotechnology and pharmaceutical companies has been initiated to comply with the growing demand for innovative therapies in the region's advancing healthcare infrastructure. With favorable regulatory environments, the funding and support for CRISPR-based gene editing research and development have been estimated.

• In January 2025, MIT Technology Review published an article on mice created using a novel CRISPR-based approach in the Chinese Academy of Sciences in Beijing and colleagues, born with two fathers and have survived to adulthood. The scientists hope to use the same approach to create primates with two dads.

China is the largest market for CRISPR-based gene editing technology in the Asia Pacific. China is rapidly emerging as a global leader in CRISPR research, with heated competition with the United States. The large and expanding biotechnology industry, the presence of key vendors, a favorable regulatory ecosystem, and government support and funding for CRISPR gene editing innovation and development are significant factors contributing to the market growth. Industries like biotechnology, pharmaceuticals, and agriculture are the major adopters of CRISPR-based gene editing technology in China.

European Robust Research Sector Drives the Market

Europe is witnessing notable growth in the global CRISPR-based gene editing market due to the region's robust research institutes and collaboration between research, universities, and pharmaceutical companies. A favorable regulatory environment and government support, and funding for research and development are the key factors contributing to market growth. Europe approaches significant activities to facilitate the approval of gene editing therapies and to create further opportunity space for the market. Germany is leading the market with the country's increased focus on precision medicine. The significant investments in genomic research, such as cancer treatments and regenerative medicine, drive the market expansion in Germany.

Market Overview

The CRISPR-based gene editing market is growing rapidly, mainly due to increased awareness and diagnosis of genetic disorders, such as cystic fibrosis, sickle cell disease, and muscular dystrophy. CRISPR-based gene editing is the technology that allows scientists to precisely modify DNA by using “molecular scissors” called Cas9. The increased genetic disease prevalence drives demand for effective gene editing technologies like CRISPR. The need for advanced delivery methods and safety profiles, along with a preference for CRISPR-based gene editing technology. Biotechnology industries are the major applications of CRISPR-based gene editing technologies, widely used for studying genes and their functions, creating disease models, and developing novel therapies.

The increased demand for personalized medicines is driving the adoption of CRISPR-based gene editing technology to treat genetic diseases. The rapid utilization of this technology in agriculture further contributes to the market growth. This technology can help to improve crop yields, improve nutritional content, and improve disease-resistance abilities. Growing investments and support for gene editing research and development are allowing access to CRISPR-based gene editing approaches. Additionally, ongoing collaborations between research institutes, universities, pharmaceutical and biotechnology companies, and government institutes are emerging novel opportunities for the technology.

• In December 2023, Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy was the first-ever CRISPR-based medicine, receiving approval from the U.S. Food and Drug Administration (FDA) for treating sickle cell disease (SCD) in patients 12 years and older.

CRISPR-Based Gene Editing Market Growth Factors

• Adoption in biotechnology and pharmaceuticals: CRISPR-based gene editing has witnessed rapid adoption in the biotechnology and pharmaceutical industries for the development of novel therapies and treatments, driving the CRISPR-based gene editing market.
• Demand for personalized medicine: The increased awareness of genetic disease and the importance of efficient treatment solutions have increased the demand for personalized medicines, driving demand for CRISPR-based gene editing solutions.
• Technological advancements: continuous advancements in CRISPR technology, like improving precision, efficiency, and safety, build people's trust in CRISPR-based gene editing tools.
• Investments in the research and development industry: The pharmaceutical companies and government organizations increased investment initiatives for the research and development sector, allowing advanced approaches in CRISPR technology.
• Favorable regulatory environment: the regulatory support for innovation and development of CRISPR-based gene editing therapies is highly influencing market expansion.
• Agriculture application: Rising emphasis on adopting gene editing technologies for improving crop yield, lifespan, and disease resistance capabilities is creating space for the adoption of CRISPR-based gene editing technology.

Market Scope

Market Dynamics

Drivers

High prevalence of genetic disorders

The increased prevalence of genetic disorders is the major driver of the global CRISPR-based gene editing market. The incidence of genetic disorders such as sickle cell anemia, cystic fibrosis, and muscular dystrophy has rapidly increased around the globe, driving the adoption of CRISPR-based gene editing technology. Ongoing advancements in CRISPR technologies enhance safety, precision, and efficacy, making them ideal treatment solutions for genetic disorders.

Awareness of genetic disorders has increased. However, the lack of treatment solutions for genetic diseases has driven attention toward the potential of CRISPR-based gene editing solutions. Additionally, CRISPR technology can provide disease detection and monitoring and help to develop personalized therapies depending on individual genetic profiles.

Restraint

Efficiency and safety concerns

CRISPR-based gene editing can sometimes edit unintended genome parts, leading to off-target effects. This can further create mosaicism and non-specific and hazardous gene modifications. The risk of CRISPR to genomic instability and trigger an immune response, leading to unintended changes to the genome, inflammation, and other adverse effects. The precision-driven therapies face major off-target consequences. Additionally, the evaluation of viral delivery systems has created controversy over adverse events following clinical trials. The CRISPR-based gene editing technology needs to advance efficient and safe delivery systems.

Opportunity

Technological advancements in base editing and prime editing

The CRISPR-based gene editing technology is transforming novel approaches through advancements in base and prime editing using CRISPR-Cas9 technology. These technological advancements enable more precise and versatile genetic modifications. Base editing allows direct and irreversible conversion of one DNA base to another without making a double-stranded break in the genome. Prime editing combines CRISPR technology with base editing, allowing more precise and efficient gene editing.

The increased need for safer and more reliable options for gene editing is taking place. Advancements in base and prime editing enable more flexibility and safety of CRISPR technology. Base and prime editing is considered ideal for therapeutic application to treat genetic diseases like sickle cell anemia and muscular dystrophy. Advancements in base and prime editing improve CRISPR technology capabilities for the development of new therapeutic and agricultural applications.

• In October 2024, a team at the Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, 02142, U.S., presented the in vitro screening of potential therapeutic base-editing targets for the USH2A gene and empirically validated the efficiency of adenine and cytosine base editor/guide combinations for correcting 35 USH2A mutations.

Product Insights

The kits and reagents segment held the biggest CRISPR-based gene editing market share in 2024. The demand for kits and reagents, including CRISPR kits, enzymes, and libraries, has increased, driven by their essential role in research and applications. The expanding research in gene editing tools is driving the need for kits and reagents. The various applications of kits and reagents in agriculture research, disease research, and biomedical research are increasing the adoption rate. Under the services segment, the CRISPR kits sub-segment dominated. The CRISPR kits are specifically created to show the entire spectrum of gene editing products in the CRISPR reaction. The increased adoption of CRISPR kits in CRISPR technology-based drug discovery and gene therapy fueling the segment growth.

The services segment is expected to grow at the fastest CAGR over the forecast period due to increased demand for outsourcing gene editing services for precise and efficient gene editing solutions. Gene editing is a complex procedure that requires specialized expertise and equipment. The need for outsourcing gene editing services has increased due to its cost-effective nature with high capabilities for small and medium-sized research institutes and biotechnology companies.

Under the services segment, the contract research organizations (CRO) sub-segment held a significant share. The risk of R&D complexity, the need for skilled workforces, and increased demand for outsourcing research activities drive demand for Contract Research Organizations (CROs) services in clinical trials and genetic data management.

Gene Editing Modality Insights

The ex vivo editing segment led the CRISPR-based gene editing market in 2024 due to rapid advancement in clinical trials and base and prime technologies. The ex vivo editing modality allows precise and controlled gene editing to reduce the risk of off-target effects. Flexibility, control, and versatility of ex vivo editing have generated a spectacular impact on therapeutic approaches for sickle cell anemia and β-thalassemia and in developing CAR-T therapies for cancer. Safety, technical feasibility, and targeted condition advantages of ex-vivo editing are increasing the popularity. Also, ex vivo editing has less strict regulatory requirements compared to in vivo editing.

However, the in vivo editing segment is estimated to grow at the fastest CAGR over the forecast period. The direct gene editing nature of in-vivo editing helps to reduce the need for ex-vivo editing, cell transplantation, and cell extraction, making them promising avenues for therapeutic applications. In-vivo editing reduces the risk of complexity and improves efficacy by allowing precise and efficient gene editing. The use of in vivo editing has increased in the treatment of genetic diseases, cancer, and infectious diseases.

• In August 2024, YolTech Therapeutics unveiled that the company dosed the first two patients in an Investigator-Initiated Trial of YOLT-203.  This is the in vivo gene-editing therapeutic candidate development trial using YolTech's proprietary YolCas12™ system.

Technology Insights

The CRISPR/Cas9 technology segment dominated the global CRISPR-based gene editing market in 2024. The segment growth is accounted for due to its wide adoption in research and development. The Cas9 is a powerful technology for research, clinical trials, and potential therapeutic applications. These technologies reduce disrupting of disease-causing genes with great precision and efficiency. The advancements in CRISPR-associated protein 9 (Cas9) gene-editing technology are expected to enhance permanent disease-treating capabilities.

• In January 2025, a mouse model constitutively expressed enhanced Acidaminococcus sp. Cas12a (enAsCas12a) with an mCherry reporter, demonstrating successful in vitro and in vivo gene editing, was presented by researchers from Australia, the United States, and China.

The CRISPR/Cas12 technology segment is projected to grow at the fastest rate during the forecast period. The adoption of CRISPR/Cas12 Technology has increased in the agriculture and biomedicine industries. This technology is highly efficient and specific in gene editing applications. Cas12 technology allows gene editing without separating guide RNA, which makes it advantageous for an efficient and more streamlined process. Cas12 technology is being used for various applications, including gene therapy, cancer, and agricultural biotechnology.

Application Insights

The therapeutic applications segment contributed the highest CRISPR-based gene editing market share in 2024 due to the increased prevalence of genetic disease and demand for personalized medicines. The adoption of CRISPR-based gene editing therapy has increased research and developments and clinical trials for developing novel, safe, and efficient therapies. Additionally, technological advances such as improved efficiency, specificity, and safety draw scientists' attention toward them. Regulatory support for CRISPR-based gene editing research and development plays a vital role in segment growth.

Under the therapeutic application segment, the gene therapy sub-segment held a significant share. Gene therapy has the largest market share, driven by the increased use of the advent of CRISPR technology for the treatment of genetic disorders. Biotechnology and pharmaceutical companies are heavily investing in the research and development of CRISPR-based gene therapies. However, the cancer therapy segment will grow rapidly in the upcoming period due to increasing developments of CRISPR-based gene editing techniques for cancer treatments. CRISPR-based gene editing techniques are rapidly being used to repair mutations or deletions in tumors. The ongoing CRISPR-based gene editing technology engineering CAR-T cells with enhanced anti-cancer capabilities holds immense promise for the future.

The agriculture and livestock segment is expected to show the fastest growth over the projected period. The segment growth is poisoned due to the increased adoption of CRISPR-based gene editing technology in agriculture and livestock applications, including improved crop yield, productivity, disease resistance, and nutritional value. The growing global population and need for food production. The trend for sustainable agriculture and nutritionist animal food is driving demand for CRISPR technology in agriculture and livestock areas.

Under the agriculture and livestock segment, the cancer therapy segment held the largest share. The adoption of CRISPR technology has witnessed rapid growth in agriculture applications such as crop improvements to enable precise and efficient modifications. CRISPR technology provides herbicide tolerance, pest resistance, and drought tolerance properties to the crops. The CRISPR-based gene editing technology helps to improve capabilities of disease resistance, yield value, and nutritional value, ultimately boosting agricultural productivity and sustainability.

• In March 2025, a new CRISPR-Cas system with the potential to add to the capabilities of the already transformational gene editing and DNA manipulation toolbox was discovered by researchers at Duke University and North Carolina State University.

End User Insights

The biotechnology and pharmaceutical companies segment dominated the CRISPR-based gene editing market in 2024. The biotechnology and pharmaceutical companies are leading in the research, development, and clinical trials for targeted therapies. The increased prevalence of genetic diseases is further contributing to the increasing numbers of research and developments in biotechnology and pharmaceutical areas. The rising research and development activities for personalized medicines are driving the adoption of CRISPR-based gene editing technology in these companies. Additionally, biotechnology and pharmaceutical companies are heavily investing in research and development to enhance CRISPR-based gene editing technology capabilities.

On the other hand, the agricultural and livestock Industry segment is projected to grow at the fastest rate during the forecast period. One of the factors contributing to this growth is the increased demand for sustainable agriculture. The need for advanced technologies to improve crop yield, animal health, and productivity in agriculture and livestock is driving the adoption of CRISPR-based gene editing technology. CRISPR technologies improve crop yield and disease resistance capabilities. This technology reduces the need for antibiotics and improves animal welfare, driving adoption to enhance health and productivity. The technology enables the development of animal livestock, improved meat and milk production, and disease resistance abilities.

CRISPR-Based Gene Editing Market Companies

• CRISPR Therapeutics AG
• Agilent Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• GeneCopoeia, Inc.
• Synthego Corporation
• System Biosciences LLC
• ToolGen, Inc.
• Rockland Immunochemicals, Inc.
• Horizon Discovery Group PLC
• Abcam, Inc.
• Applied StemCell, Inc.
• Cellecta, Inc.

Recent Developments

• In January 2025, scientists at the Institute of Cancer Research (ICR) in the UK developed a method for simultaneous activation, repression, and knockout of genes within a single cell by using CRISPR technology.
• In January 2025, researchers in the UK and the United States published a study about the use of prime-editing technology to insert recombinase sites into repetitive DNA sequences, exploring the human genome's structural flexibility. This study allows scientists to create genomic rearrangements in human cell lines, including deletions, inversions, and translocations across all chromosomes. 

Segment Covered in the Report

By Product

• Kits and Reagents
  
  • CRISPR Kits 
  • Guide RNA 
  • Enzymes 
  • Other Reagents 
• Services 
  
  • Gene Editing Services 
  • Contract Research Organizations (CROs)

By Gene Editing Modality

• Ex-Vivo Editing 
• In-Vivo Editing 

By Technology

• CRISPR/Cas9 Technology 
• CRISPR/Cas12 Technology 
• CRISPR/Cas13 Technology 
• Base Editing 
• Prime Editing 
• Epigenetic Editing 
• Others 

By Application

• Therapeutic Applications 
  
  • Gene Therapy 
  • Cancer Therapy 
  • Infectious Disease Treatment 
  • Regenerative Medicine 
• Agriculture and Livestock 
  
  • Crop Improvement 
  • Livestock Modifications 
• Industrial Biotechnology 
  
  • Microbial Engineering 
  • Biomanufacturing 

By End User

• Academic and Research Institutes 
• Biotechnology and Pharmaceutical Companies 
• Agricultural and Livestock Industry 
• Hospitals and Clinics 
• Contract Research Organizations (CROs)

By Geography

• North America 
• Europe 
• Asia Pacific 
• Latin America 
• Middle East and Africa